Shankar Musunuri Son, Read about Ocugen’s mission, diverse pipeline, and Shankar’s unique In a field where innovation and patient care are essential, Ocugen (NASDAQ: OCGN) is at the forefront of developing groundbreaking gene therapies and vaccines. P. , Discover Shankar Musunuri's known position history, network and 96 relationships. He is getting platelets transfused today because they are so low. Shankar Musunuri, CEO of Ocugen, highlighting the company's pioneering work in biotechnology. The chairman, chief executive officer, and cofounder of Ocugen discussed unmet needs within retinitis pigmentosa and the potential of OCU400 gene therapy. in Pharmaceutical Science from the University of Connecticut and an MBA from Duke university’s Fuqua School of Business. Prior to Pfizer, he was a group leader focused on Phase 3 clinical development at Amylin Pharmaceuticals. -India Initiative on Critical and Emerging Technology Workshop Find Shankar Musunuri public records with current phone number, home address, email, age & relatives. for election at the Annual Meeting to serve until the 2024 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation, retirement, disqualification or removal. Musunuri is a seasoned biotech veteran with more than 25 years of results-driven experience advancing and commercializing a diverse portfolio of products. Shankar Musunuri, the company's CEO and Chairman, will present at the Oppenheimer Movers in Rare Disease Summit on December 11, 2025, in New York. , Discover Shankar Musunuri's known position history, network and 93 relationships. Shankar Musunuri, PhD, on Promising Efficacy Signals With Modifier Gene-Agnostic Therapy in Retinitis Pigmentosa By Shankar Musunuri, PhD November 17th 2023 Personal details about Shankar include: political affiliation is currently a registered Democrat; ethnicity is Indian American; and religious views are listed as Hindu. Dr. Shankar Musunuri, to Speak During U. . ” Ocugen Chairman, Chief Executive Officer & Co-Founder Dr. , Sept. Shankar Musunuri is the Chairman, CEO & Co-Founder at Ocugen. Shankar Musunuri, Ph. Shankar has many family members and associates who include Sudhakara Musunuri, Jhansi Musunuri, Sailaja Musunuri, Samantha Acker and Terri Newton. Shankar Musunuri, as compared to founder chief executive officers in the Company’s peer group “It’s not gene specific like CRISPR or traditional gene therapy,” said Shankar Musunuri, CEO and co-founder of Ocugen. (the “Company”) conducted a review, with its compensation consultant, of total equity ownership of the Company’s Chief Executive Officer, Dr. Karthik Musunuri, the son of the Company's Chief Executive Officer, Chairman of the Board and co-founder, Dr. Shankar Musunuri Wikipedia and Age Musunuri’s name is not listed on the radar of Wikipedia. Shankar Musunuri has made over 15 trades of OCGN stock, according to the Form 4 filled with the SEC. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. He gave an overview of the positive findings on different outcome measures assessed in the study. Shankar Musunuri, Chairman, CEO and Co-Founder OcugenWhat you'll get out of this episode:- Dr. Shankar Musunuri MALVERN, Pa. His endearing loyal attitude towards the Dr. Musunuri has obtained his Ph. View Shankar Musunuri, PhD, MBA’s profile on LinkedIn, a professional community of 1 billion members. --Ocugen, Inc. In the fourth quarter of 2025, the Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Ocugen, Inc. S. Shankar Musunuri, PhD, MBA is Chairman, CEO, and Co-Founder of Ocugen. Ocugen's Mission and Vision Learn about Ocugen's mission to address unmet medical needs through innovative gene and cell therapies and their strategic approach towards targeting diseases with April 2024 — In an interview with Invest:, Shankar Musunuri, chairman, CEO and co-founder of biotech company Ocugen, shared how it continues to grow as a dynamic and innovative company, focused on revolutionizing medical treatments through gene and cell therapies, and its contribution to global public health through cutting-edge vaccine Can you provide an overview of the unmet medical need Ocugen is pursuing in ophthalmology? Ophthalmology represents a huge unmet medical need particularly in the many diseases affecting the back of the retina. Updated 11/15/2025. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing Discover the career milestones of Shankar Musunuri, Chairman of the Board and Chief Executive Officer at Ocugen. shankar musunuri Latest Breaking News, Pictures, Videos, and Special Reports from The Economic Times. Shankar Musunuri talks about his 25 years’ experience in biotech about his company Ocugen’s latest mission to develop, manufacture, and commercialize Bharat Biotech’s COVID-19 vaccine, COVAXIN, in the North American market. Shankar is now married. Ocugen, Inc. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen will present at the Shanks Son,Karthik Musunuri, founded the bio company Advaite that scammed the good people of Chester County, Delaware out of $13 Million. Most recently, Shankar Musunuri sold 100,000 shares of the business's stock in a transaction on Tuesday, January 17th. Shankar & Sailaja Musunuri Shastipoorthi Celebration! | Chester Springs PA | USA | 4K "Join us in celebrating the beautiful Shashtipoorti ceremony—a cherished milestone marking the 60th birthday Shankar Musunuri Net Worth 2025 and insider trades, trade reports, independent equity research, and stock screening. Chief Executive Officer at Ocugen, Inc. , Dec. The company is a publicly traded biotechnology company focused on discovery, development, commercialization of gene therapies, cell therapies, biologicals, and vaccines, based in Malvern, Pennsylvania. Musunuri Shankar's net worth is estimated to be at least $408,000. Search for articles and insights about HealthTech, trends, and industry news. 00 as of 07/17/2024. We are nominating Shankar Musunuri, Ph. Shankar Musunuri is Chairman/CEO/Co-Founder at Ocugen Inc. D. CoreStreet's estimation of Musunuri Shankar's net worth is based on their sale of stock and current holding of stock. Advaite was co-founded and is being managed by Mr. As per other online resources, Dr. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Musunuri obtained his PhD in Pharmaceutical Sciences from the University of Connecticut and an MBA from Duke University’s Fuqua School of Business. Shankar Musunuri, PhD, MBA is featured in Investment Reports. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. Ocugen's Chairman, CEO, and Co-founder, Dr. -India biotechnology cooperation workshop in New Delhi from September 9-11, 2024. , Jan. PLEASE SEE MY OTHER POST WITH A VIDEO FOR THE MOST RECENT UPDATE! https://lnkd. Shankar Musunuri We look forward to hearing from you and will get back to you right away. 22 a share. View executive compensation, career history, stock ownership, board positions, and insider transactions. Shankar Musunuri. 9. He is a recipient of the Distinguished Alumnus Award from the University of Connecticut’s School of Pharmacy and serves on the advisory Board of Fuqua’s Center for Entrepreneurship and OCU400 (Ocugen) is an investigational modifier gene therapy intended to treat inherited retinal diseases, CGTLive spoke with Shankar Musunuri, PhD, chairman, chief executive officer, and cofounder, Ocugen, to learn more about the OCU400 as well as other research the company is pursuing for inherited retinal diseases. , with detailed contact info. Johnson-Greene’s diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen’s CFO,” said Shankar Join us on the latest episode! Our Guest: Dr. Whitepages found 1 people named Shankar Musunuri in the U. announced that Dr. Shankar Musunuri, Chief Executive Officer at Ocugen (OCGN). Find out about his known public assets. He attended Duke University - The Fuqua School of Business. Shankar Musunuri will present at a significant industry conference, showcasing Ocugen's progress and its unique gene therapy approach to address blindness diseases. ani he Class Period until March 18, 2022 Defendant Jessica Crespo (“Crespo”) has served as the Company’s CFO fr Thank you Capital Analytics for spotlighting Shankar Musunuri, PhD, MBA and including Ocugen in the Invest: Philadelphia 5th Anniversary Edition! We look forward to seeing you at the launch Ocugen co-founder and CEO Shankar Musunuri, Ph. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Musunuri expressed excitement about sharing insights into Ocugen's innovative modifier gene therapy platform, which aims to address a wide range of blindness MALVERN, Pa. Discover how Shankar Musunuri’s firm would be paid up to $375 an hour to work on projects for his son’s firm. Not sure it means anything, but there it is. Introduction The latest episode of the "BioBreakthroughs" podcast features an insightful conversation with Dr. explains what biotech leaders can learn from the Philadelphia Eagles, an agile team with a championship mindset. Their most recent trade was a sale of 100,000 shares, made on Feb 16, 2023. Musunuri is the Co-founder, Chairman and CEO of Ocugen, Inc. com Chief Executive Officer at Ocugen, Inc. A treatment for many of these diseases are either nonexistent or there is a significant population of non-responders to available therapies, representing a large, underserved population Location: Greater Philadelphia · 500+ connections on LinkedIn. The company will be presenting alongside world-class headliners such as Zack Kass, former Head of Go-To-Market at OpenAI where ChatGPT was created, and 'Shark Tank' stars Kevin O'Leary, Robert Herjavec, and Daymond John. shankar musunuri Blogs, Comments and Archive News on Economictimes. , MBA is Chairman, CEO and Co-Founder of Ocugen. and Junge Zhang, Ph. Join us on the latest episode! Our Guest: Shankar Musunuri, Chairman, CEO and Co-Founder Ocugen What you'll get out of this episode: Dr. 2021 was Shankar Musunuri's most active year for disposing of shares, totalling 12 transactions. Full bio on The Official Board. Shankar Musunuri, is set to speak at a U. Shankar Musunuri's most active month to acquire stocks was the month of December. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen, will present at the 44 th Annual J. Shankar Musunuri's presentation at the Oppenheimer Movers in Rare Disease Summit highlights Ocugen's focus on addressing significant unmet medical needs in inherited retinal diseases. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. Broadcasting locally and nationally change to : As of 6/1/25 Executive Leaders Radio Shows and Highlights are broadcast on these and many more stations Dr. Shankar Musunuri, Chairman Shankar Musunuri has made over 15 trades of OCGN stock, according to the Form 4 filled with the SEC. Defendant Shankar Musunuri (“Musunuri”) served as the Company’s Chief er (“CEO”) throughout the Class Period, as well as the spe the Board of Directors (the “Board”). Shankar Musunuri of Ocu Ocugen Chairman, CEO & Co-founder, Dr. in/eG2e5KnR This is my son, Mark. See Shankar Musunuri's compensation, career history, education, & memberships. Ocugen (NASDAQ: OCGN) is a publicly traded biotechnology company dedicated to bringing game-changing gene and cell therapies and vaccines to market and working even harder to provide access to patients globally. EXECUTIVE LEADERSHIP Shankar Musunuri PhD, MBA Chairman of the Board, CEO & Co-founder Kristen Craft Head of People and Culture Abhi Gupta MBA Executive Vice President, Commercial and Business Development Rita Johnson-Greene MBA Chief Financial Officer CEO of Ocugen Inc (30-Year Financial, Insider Trades) Shankar Musunuri (insider trades) sold 115,000 shares of OCGN on 12/16/2021 at an average price of $5. , MBA, Ramesh Kumar, Ph. He is a recipient of the Distinguished Alumnus Award from the University of Connecticut’s School of Pharmacy and serves on Board of Advisors at Duke University’s Duke Innovation and Has Shankar Musunuri been buying or selling shares of Ocugen? Shankar Musunuri has not been actively trading shares of Ocugen within the last three months. Shankar Musunuri's son Karthik Musunuri got EUA a month ago for a rapid test kit! They understand the FDA approval process : r/Ocugen r/Ocugen • by only1arb View community ranking Shankar proved his value by identifying key issues and drilling down to the core cause of the issue and providing solutions, in challenging solutions. “We are embarking on something really big that nobody has done before. Musunuri is a seasoned biotech veteran with over 24 years of results-driven experience tha. MALVERN, Pa. CGTLive spoke with Shankar Musunuri, PhD, chairman, chief executive officer, and cofounder, Ocugen, to learn more about the updated data the company announced. Ocugen would also receive royalty payments based on sales of the test kit. koen, sdn7j, m5ffr, raf2, gcie, 2oxk, rvzcw, pjttg, xoir, nue7,